Shaik Junaid, Pillay Manormoney, Jeena Prakash
Department of Paediatrics and Child Health, School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4000, South Africa; Faculty of Health Sciences, Durban University of Technology, Steve Biko Road, Berea, Durban, 4000, South Africa.
Medical Microbiology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4000, South Africa.
Paediatr Respir Rev. 2024 Dec;52:44-50. doi: 10.1016/j.prrv.2024.01.005. Epub 2024 Feb 17.
Tuberculosis (TB) is one of the most common causes of mortality globally with a steady rise in paediatric cases in the past decade. Laboratory methods of diagnosing TB and monitoring response to treatment have limitations. Current research focuses on interrogating host- and/or pathogen-specific biomarkers to address this problem.
We reviewed the literature on host-specific biomarkers in TB to determine their value in diagnosis and treatment response in TB infected and HIV/TB co-infected children on anti-tuberculosis treatment.
While no single host-specific biomarker has been identified for diagnosis or treatment responses in children, several studies suggest predictive biosignatures for disease activity. Alarmingly, current data on host-specific biomarkers for diagnosing and assessing anti-tuberculosis treatment in TB/HIV co-infected children is inadequate. Various factors affecting host-specific biomarker responses should be considered in interpreting findings and designing future studies within specific clinical settings.
结核病是全球最常见的死亡原因之一,在过去十年中儿科病例稳步上升。结核病的实验室诊断方法和治疗反应监测方法存在局限性。目前的研究集中在探究宿主特异性和/或病原体特异性生物标志物以解决这一问题。
我们回顾了关于结核病宿主特异性生物标志物的文献,以确定其在接受抗结核治疗的结核病感染儿童和艾滋病毒/结核病合并感染儿童的诊断和治疗反应中的价值。
虽然尚未确定单一的宿主特异性生物标志物用于儿童结核病的诊断或治疗反应,但多项研究提示了疾病活动的预测生物特征。令人担忧的是,目前关于用于诊断和评估艾滋病毒/结核病合并感染儿童抗结核治疗的宿主特异性生物标志物的数据不足。在特定临床环境中解释研究结果和设计未来研究时,应考虑影响宿主特异性生物标志物反应的各种因素。